Rexahn Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing treatments for cancer, central nervous system diseases, and other medical disorders. It has several clinical stage product candidates that are being tested for their efficacy in treating colon, lung, and pancreatic cancer. The company has several strategic partnerships with universities, research institutions, and pharmaceutical companies. For more information, please visit the company’s website at www.rexahn.com.